Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metronidazole + neomycin sulfate + nystatin
- Development stage
- Unknown
- Lead developer
- Antibiotice
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
metronidazole + neomycin sulfate + nystatin is a fixed-dose combination anti-infective therapy formulated as vaginal ovules for the treatment of mixed vaginal infections. Developed and manufactured by Antibiotice, it combines the antimicrobial properties of three distinct agents to provide broad-spectrum coverage. Metronidazole is a nitroimidazole that targets anaerobic bacteria and protozoa by causing DNA strand breakage. Neomycin sulfate is an aminoglycoside antibiotic that inhibits protein synthesis in aerobic bacteria by binding to the 30S ribosomal subunit. Nystatin is a polyene antifungal that binds to ergosterol in the fungal cell membrane, leading to increased permeability and cell death. This combination is primarily indicated for bacterial vaginosis, non-specific vaginitis, and vulvovaginal candidiasis.
- Brand names
- GynovulTergyax
- Other names
- metronidazole/neomycin/nystatin
02
Targets
ErgosterolNeuraminidaseBacterial Ribosome
Beyond the preview
Go deeper on metronidazole + neomycin sulfate + nystatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metronidazole + neomycin sulfate + nystatin.